MorphoSys AG : MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer

 MorphoSys AG : MorphoSys AG : MorphoSys to Host Conference Call on Strategic
Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with
                               Multiple Myeloma

MorphoSys AG / MorphoSys AG : MorphoSys to Host Conference Call on Strategic
Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with
Multiple Myeloma . Ad hoc announcement according to § 15 WpHG. Processed and
transmitted by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.

On June 26, 2013, MorphoSys and Celgene Corporation announced an agreement to
jointly develop MOR202 globally and to co-promote MOR202 in Europe. MOR202 is
a fully human monoclonal antibody targeting CD38 to treat patients with
multiple myeloma (MM) and certain leukemias.

Today at 4:00 p.m. CET (10:00am EST, 03:00pm BST), the Management Board of
MorphoSys AG will host a public conference call and webcast to present more
information on the transaction.

Dial-in number for the Conference Call (listen-only):

Germany: +49 89 2444 32975

For U.K. residents: +44 20 3003 2666

For U.S. residents: +1 202 204 1514

MorphoSys offers participants the opportunity to follow the presentation
through a simultaneous slide presentation online at http://www.morphosys.com.

An audio  replay  and manuscripts  of  the  conference will  be  available  on 
www.morphosys.com/conference-calls in due course.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit http://www.morphosys.com.

HuCAL^®, HuCAL  GOLD^®,  HuCAL PLATINUM^®,  CysDisplay^®,  RapMAT^®,  arYla^®, 
Ylanthia^® and  100 billion  high potentials^®  are registered  trademarks  of 
MorphoSys AG.

Slonomics^® is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a 
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning  the 
MorphoSys group of companies. The forward-looking statements contained  herein 
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties.  Should actual conditions  differ from the  Company's 
assumptions, actual results  and actions  may differ  from those  anticipated. 
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.





For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Conference Call Alert (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
HUG#1712349

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
 
Press spacebar to pause and continue. Press esc to stop.